We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Oncology Rejections Continue With Negative Opinion on Pfizer’s CML Drug
NICE Oncology Rejections Continue With Negative Opinion on Pfizer’s CML Drug
July 16, 2013
The UK’s cost agency said July 16 it will not recommend Pfizer’s Bosulif for previously treated patients with chronic myeloid leukemia (CML), citing its high price tag and limited evidence of its benefit compared to other treatments in terms of the estimated effect on overall survival.